New Antidepressant 2025. FDA approves a new antidepressant Brintellix LA Times This article explores the newest antidepressants introduced in recent years: gepirone (Exxua), esketamine (Spravato), brexanolone (Zulresso), zuranolone (Zurzuvae), and dextromethorphan-bupropion (Auvelity). Approved in 2024, Zurzuvae represents a breakthrough as the first oral medication specifically designed for postpartum depression, targeting neurosteroids to regulate hormonal imbalances
Antidepressant Medications Classes, Doses & Side Effects Manlove Brain + Body Health from www.manlovehealth.com
For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will soon be available in the market In 2025, Zuranolone (Zurzuvae) is emerging as a key player in depression treatment, particularly for postpartum depression
Antidepressant Medications Classes, Doses & Side Effects Manlove Brain + Body Health
Approved in 2024, Zurzuvae represents a breakthrough as the first oral medication specifically designed for postpartum depression, targeting neurosteroids to regulate hormonal imbalances This ongoing challenge has driven researchers to explore novel mechanisms and approaches to treating depression, leading to the development of new medications and therapies that we'll explore in this article. From psychedelic-assisted therapies to precision psychiatry and cutting-edge technological interventions, the mental health care landscape has evolved dramatically
Introduction to Antidepressants PsychDB. Neurosteroids have been recently approved and their rapid benefit may. This article explores the newest antidepressants introduced in recent years: gepirone (Exxua), esketamine (Spravato), brexanolone (Zulresso), zuranolone (Zurzuvae), and dextromethorphan-bupropion (Auvelity).
Sharp Rise Reported in Older Americans’ Use of Multiple Psychotropic Drugs The New York Times. Koenig hopes to solve the current issues with antidepressants via the novel neuroplastogen, DLX-001, currently under study for patients with MDD. For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will soon be available in the market